Heat shock protein 90 inhibition effective and safe option against Hidradenitis Suppurativa
Written By : Jacinthlyn Sylvia
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-01-09 05:00 GMT | Update On 2024-01-09 06:27 GMT
Advertisement
In a recent clinical trial discovered promising outcomes of heat shock protein 90 inhibition by RGRN-305 for individuals suffering from moderate to severe Hidradenitis Suppurativa (HS), a painful immune-mediated disorder. This results were published in Journal of American Medical Association.
The randomized clinical study was conducted from September 22, 2021, to August 29, 2022 at the Department of Dermatology, Aarhus University Hospital in Denmark. The study included 15 patients who met eligibility criteria-aged 18 or older with moderate to severe HS and aimed to evaluate the feasibility of using RGRN-305, a heat shock protein 90 inhibitor in treating the disorder.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.